Recruiting Amyloidosis Studies in Phoenix
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis....
A Study of AMDX-2011P in Participants With CAA
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (...
About Amyloidosis Clinical Trials in Phoenix
Amyloidosis is a group of diseases in which abnormal proteins (amyloids) build up in organs and tissues, impairing their function. Types include AL, AA, and ATTR amyloidosis. Treatment depends on the type and may include chemotherapy, organ transplant, or targeted therapies.
There are currently 2 amyloidosis clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 116 participants. Research is being sponsored by Alexion Pharmaceuticals, Inc., Amydis Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Amyloidosis Clinical Trials in Phoenix — FAQ
Are there amyloidosis clinical trials in Phoenix?
Yes, there are 2 amyloidosis clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Phoenix?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.
Are clinical trials in Phoenix free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.
What amyloidosis treatments are being tested?
The 2 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for amyloidosis.
Data updated March 2, 2026 from ClinicalTrials.gov